The U.S. smart pills market is projected to grow significantly, reaching approximately $619.10 million by 2033, driven by advancements in AI-powered capsule endoscopy and increasing demand for non-invasive gastrointestinal diagnostics.
The market, valued at $265.40 million in 2025, is expected to expand at a compound annual growth rate (CAGR) of 12.9% from 2026 to 2033. Key factors contributing to this growth include a rise in gastrointestinal disorders, a shift towards minimally invasive procedures, and the integration of digital health technologies in clinical settings. Smart pills are increasingly utilized for various applications, such as monitoring drug adherence and enhancing diagnostic accuracy, thereby reducing the need for invasive interventions.
Technological innovations, including AI-enabled image analysis and wireless communication, are enhancing the efficiency of diagnostics and personalizing treatment plans. The ongoing trend towards value-based healthcare and increased healthcare spending further supports the adoption of smart pill technologies, particularly among aging populations and patients with chronic conditions.
Major players in this market include Medtronic, CapsoVision, and Olympus, who are focused on advancing capsule endoscopy systems and digital adherence solutions. As competition intensifies, companies are prioritizing innovations that improve diagnostic accuracy and patient comfort, indicating a robust future for smart pills in the healthcare landscape.